Mylan announces new cost-saving options for EpiPen users
Sep 09 2016 by Johnny Bowman
Mylan CEO Heather Bresch is the newest pharmaceutical exec to face similar criticism after she struggled to justify hiking the price of the EpiPen by more than 400 percent in the past decade.
"There's no question: the system is broken", Bresch says.
Democratic Senator Amy Klobuchar, whose daughter relies on EpiPen, has called on the Federal Trade Commission to launch an anti-trust investigation. "The price is what Medicare, Medicaid and insurance companies pay".
A two-pack of EpiPens has gone from $100 in 2009 to more than $600 now.
However, the price hike remains troublesome to users, parents of users and schools.
Mylan executives have vowed to make the drug more affordable for patients in need, but the pledge was not enough for Parker, and on Thursday (25Aug16), the concerned mum took to Instagram to attack the company.
Pharmaceutical and biotech industries can fuel American innovation, and combat debilitating diseases, Clinton said in the statement Wednesday. "All involved must also take steps to help meaningfully address the USA health care crisis, and we are committed to do our part to drive change, in collaboration with policymakers, payors, patients and health care professionals".
"We're just seeing this as one of the most recent, maybe more egregious examples of a drug price going from a fairly reasonable price to something a little bit out of hand", said Dan Wearsch of Pharmacy Care in Canfield.
Hanjin bankruptcy puts global sea freight in turmoil
Many port authorities and port service providers are demanding cash to work on Hanjin ships, the Hanjin spokeswoman said. Hanjin Shipping is one of the largest ocean shippers in the world, with a large terminal in Long Beach.